{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:11:40Z","timestamp":1779919900282,"version":"3.53.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12328-022-01605-9","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T05:02:42Z","timestamp":1645160562000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Two cases of rapid progression of esophageal varices after atezolizumab\u2013bevacizumab treatment for hepatocellular carcinoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Ai","family":"Furusawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","volume":"68","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526\u201349.","journal-title":"J Hepatol"},{"key":"1605_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the study of the liver","year":"2018","unstructured":"European Association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol."},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87:22\u201331.","journal-title":"Oncology"},{"key":"1605_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ph14010036","volume":"14","author":"T Hatanaka","year":"2021","unstructured":"Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals. 2021;14:36.","journal-title":"Pharmaceuticals"},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1605_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181\u2013223.","journal-title":"Liver Cancer"},{"key":"1605_CR9","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2169\/internalmedicine.6535-20","volume":"60","author":"Y Honma","year":"2021","unstructured":"Honma Y, Shibata M, Gohda T, et al. Rapid progression of liver fibrosis induced by acute liver injury due to immune-related adverse events of atezolizumab. Intern Med. 2021;60:1847\u201353.","journal-title":"Intern Med"},{"key":"1605_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.15403\/jgld-3207","volume":"30","author":"M Riveiro-Barciela","year":"2021","unstructured":"Riveiro-Barciela M, Gonzalez-Sans D, Marmolejo D, et al. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. J Gastrointest Liver Dis. 2021;30:171\u20132.","journal-title":"J Gastrointest Liver Dis"},{"key":"1605_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"101785","DOI":"10.1016\/j.clinre.2021.101785","volume":"46","author":"B Campion","year":"2021","unstructured":"Campion B, Larrey E, Wagner M, et al. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: a \u201cmenage \u00e0 trois.\u201d Clin Res Hepatol Gastroenterol. 2021;46:101785.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1605_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic nonsquamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924\u201337.","journal-title":"Lancet Oncol"},{"key":"1605_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nabpaclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359.","journal-title":"Lancet Oncol"},{"key":"1605_CR15","doi-asserted-by":"publisher","first-page":"6391712","DOI":"10.1155\/2019\/6391712","volume":"2019","author":"K Imoto","year":"2019","unstructured":"Imoto K, Kohjima M, Hioki T, et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol. 2019;2019:6391712.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181\u201390.","journal-title":"J Hepatol"},{"key":"1605_CR17","doi-asserted-by":"publisher","first-page":"e49717","DOI":"10.1371\/journal.pone.0049717","volume":"7","author":"P Fang","year":"2012","unstructured":"Fang P, Hu J, Cheng Z, et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS ONE. 2012;7:e49717.","journal-title":"PLoS ONE"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/1752-1947-2-227","volume":"2","author":"V Agarwal","year":"2008","unstructured":"Agarwal V, Sgouros J, Smithson J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. J Med Case Rep. 2008;2:227.","journal-title":"J Med Case Rep"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.15403\/jgld-3207","volume":"30","author":"M Riveiro-Barciela","year":"2021","unstructured":"Riveiro-Barciela M, Gonz\u00e1lez-Sans D, Marmolejo D, et al. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. J Gastrointest Liver Dis. 2021;30:171\u20132.","journal-title":"J Gastrointest Liver Dis"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jjco\/hyw143","volume":"47","author":"T Sugiyama","year":"2017","unstructured":"Sugiyama T, Mizuno M, Aoki Y, et al. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer. Jpn J Clin Oncol. 2017;47:39\u201346.","journal-title":"Jpn J Clin Oncol"},{"key":"1605_CR21","unstructured":"Avastin prescribing information. http:\/\/www.gene.com\/gene\/products\/information\/pdf\/avastin-prescribing.pdf. Accessed 10 Jan 2022."},{"key":"1605_CR22","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/liv.14977","volume":"41","author":"M Allaire","year":"2021","unstructured":"Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses\u2026. Liver Int. 2021;41:1734\u201343.","journal-title":"Liver Int"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01605-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:38:15Z","timestamp":1648222695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01605-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01605-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The written informed consent was obtained from patients for this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}